Floatz logo

Tgrx-1942

Cancer

Shenzhen TargetRx Co., Ltd.Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
59/ 100

Competitive context

1411 Active assets in the Cancer cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Tgrx-1942 is also rated in:

hematopoietic and lymphoid cell neoplasmDormant
C
Indicative ·
39 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →